SCHEMBL16639228

SCHEMBL16639228

c1ccc(-c2ccc3c(c2)c2cc(-c4ccccc4)ccc2n3-c2ccc3oc4ccccc4c3c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 5/20 0.46
PLA2G4A P47712 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
HPGD P15428 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
PLA2G10 O15496 1/20 0.41
AHR P35869 1/20 0.38
PGR P06401 1/20 0.38
PRKDC P78527 3/20 0.38
LMNA P02545 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CASP3 P42574 1/20 0.36
SENP7 Q9BQF6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12158843 1.00 PLA2G2A (0.46) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL12158880 1.00 PLA2G2A (0.46) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL21388941 0.99 PLA2G2A (0.45) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL18266070 0.97 PLA2G2A (0.44) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL20097820 0.97 PLA2G2A (0.44) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL18265980 0.97 PLA2G2A (0.44) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL12158884 0.97 PLA2G2A (0.45) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL20633659 0.97 PLA2G2A (0.44) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL20706752 0.97 PLA2G2A (0.44) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1
SCHEMBL18266011 0.97 PLA2G2A (0.44) PLA2G2APLA2G4ASMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10361378-B2 Organic electroluminescent device NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) 2019-07-23 US disclosed
EP-2933851-B1 ORGANIC ELECTROLUMINESCENT DEVICE NIPPON STEEL & SUMIKIN CHEM CO (JP) 2017-05-10 EP disclosed
US-9257663-B2 Organic electroluminescent element and display device SONY CORPORATION (JP) 2016-02-09 US disclosed
US-20150325796-A1 ORGANIC ELECTROLUMINESCENT DEVICE NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) 2015-11-12 US disclosed
US-20150325796-A1 ORGANIC ELECTROLUMINESCENT DEVICE NIPPON STEEL CHEMICAL & MATERIAL CO., LTD. (JP) 2015-11-12 US disclosed
US-20150171356-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND DISPLAY DEVICE MAGNOLIA BLUE CORPORATION (JP) 2015-06-18 US disclosed
US-20150171356-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND DISPLAY DEVICE MAGNOLIA BLUE CORPORATION (JP) 2015-06-18 US disclosed
EP-2861044-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND DISPLAY DEVICE Sony Corporation (JP) 2015-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10361378-B2 Organic electroluminescent device ELF3, DDT, LEF1 PLA2G2A 4329/4885PLA2G4A 4258/4885SMN1; SMN2 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.